- VIVUS Announces Date of 2017 First Quarter Business Update and Financial Results Teleconference
- VIVUS, Inc. Reacquires STENDRA(R) (Avanafil) Commercial Rights from Sanofi
- VIVUS Reports Fourth Quarter and Full Year 2016 Financial Results
- VIVUS Announces Date of 2016 Fourth Quarter Business Update and Financial Results Teleconference
- VIVUS and Selten Pharma Announce Agreement for the Development and Commercialization Rights to Treatments for Pulmonary Arterial Hypertension (PAH)
A Growing Pipeline
VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs.